Literature DB >> 17891443

Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability.

Wan Yee Lau1, Eric C H Lai.   

Abstract

BACKGROUND: Surgical resection with complete extirpation of the tumor gives the best chance of a cure for patients with hepatocellular carcinoma (HCC). However, the resectability of HCC at the time of diagnosis is low (10-30%). This article reviews the use of salvage surgery following tumor downstaging to treat unresectable HCC.
MATERIALS AND METHODS: A Medline search was undertaken from 1966 to 2005 to identify articles using the keywords "liver neoplasm," "hepatocellular carcinoma," "tumor downstaging," and "unresectable." Additional papers were identified by a manual search of the references from the key articles.
RESULTS: Eight to eighteen percent of patients with unresectable HCC responded well enough to the initial palliative treatment to downstage HCC to allow salvage surgical resection. The reported five-year survival rate after salvage surgery following tumor downstaging varied from 24.9 to 57%.
CONCLUSIONS: Although it is still unknown whether the outcome of salvage surgery following tumor downstaging is comparable to those of resectable tumors after primary resection, one clear message is that salvage surgery following tumor downstaging gives good long-term results and the possibility of a cure in a proportion of patients with unresectable HCC. The role of salvage surgery after tumor downstaging in improving disease-free and overall survival in patients with unresectable HCC should be investigated further by prospective randomized controlled trials.

Entities:  

Mesh:

Year:  2007        PMID: 17891443     DOI: 10.1245/s10434-007-9549-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  44 in total

1.  Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging.

Authors:  Tian Yang; Chuan Lin; Jian Zhai; Song Shi; Min Zhu; Nan Zhu; Jun-Hua Lu; Guang-Shun Yang; Meng-Chao Wu
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-10       Impact factor: 4.553

Review 2.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

3.  Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy.

Authors:  Nan Li; Shuang Feng; Jie Xue; Xu-Biao Wei; Jie Shi; Wei-Xing Guo; Wan-Yee Lau; Meng-Chao Wu; Shu-Qun Cheng; Yan Meng
Journal:  HPB (Oxford)       Date:  2016-05-07       Impact factor: 3.647

4.  Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.

Authors:  Yingqiang Zhang; Guihua Huang; Yu Wang; Lijian Liang; Baogang Peng; Wenzhe Fan; Jianyong Yang; Yonghui Huang; Wang Yao; Jiaping Li
Journal:  Oncologist       Date:  2016-08-02

5.  Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis.

Authors:  Zhao-Ru Dong; Peng-Fei Zhang; Cheng-Hao Wang; Chi Zhang; Jia-Bin Cai; Guo-Ming Shi; Ai-Wu Ke; Hui-Chuan Sun; Shuang-Jian Qiu; Jian Zhou; Jia Fan
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

6.  Presentation and outcomes of hepatocellular carcinoma patients at a western centre.

Authors:  Krit Kitisin; Vignesh Packiam; Jennifer Steel; Abhinav Humar; T Clark Gamblin; David A Geller; J Wallis Marsh; Allan Tsung
Journal:  HPB (Oxford)       Date:  2011-08-11       Impact factor: 3.647

7.  The recombinant chimeric antibody chHAb18 against hepatocellular carcinoma can be produced in milk of transgenic mice.

Authors:  Jingjing Wei; Xiangmin Yang; Min Zheng; Meili Wang; Yunping Dai; Zhinan Chen; Ning Li
Journal:  Transgenic Res       Date:  2010-06-12       Impact factor: 2.788

8.  Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus: a comparative study.

Authors:  Qing-he Tang; Ai-jun Li; Guang-ming Yang; Eric C H Lai; Wei-ping Zhou; Zhi-hao Jiang; Wan Yee Lau; Meng-chao Wu
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

Review 9.  Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma.

Authors:  Chihwan Choi; Gi Hong Choi; Tae Hyun Kim; Masatoshi Tanaka; Mao-Bin Meng; Jinsil Seong
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

10.  Comparison of percutaneous radiofrequency ablation and CyberKnife(®) for initial solitary hepatocellular carcinoma: A pilot study.

Authors:  Kazue Shiozawa; Manabu Watanabe; Takashi Ikehara; Yasushi Matsukiyo; Michio Kogame; Yui Kishimoto; Yusuke Okubo; Hiroyuki Makino; Nobuhiro Tsukamoto; Yoshinori Igarashi; Yasukiyo Sumino
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.